REFERENCE
European Medicines Agency.Summary of opinion (post authorisation) Pradaxa. Internet Document: [1 page], 19 Jul 2012. Available from: URL: http://www.ema.europa.eu
European Medicines Agency.Summary of opinion (post authorisation) Ozurdex. Internet Document: [2 pages], 19 Jul 2012. Available from: URL: http://www.ema.europa.eu
Rights and permissions
About this article
Cite this article
The EMA has recommended changes to the marketing authorisations for Pradaxa [dabigatran etexilate] and Ozurdex [dexamethasone].. React. Wkly. 1412, 4 (2012). https://doi.org/10.2165/00128415-201214120-00012
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128415-201214120-00012